881384-32-3

Basic information

• Product Name: Methyl 2-(4-(2-(trifluoroMethyl)benzoyl)piperazin-1-yl)thiazole-5-carboxylate
• Synonyms: Methyl 2-(4-(2-(trifluoroMethyl)benzoyl)piperazin-1-yl)thiazole-5-carboxylate;2-[4-(2-Trifluoromethylbenzoyl)piperazin-1-yl]thiazole-5-carboxylic acid methyl ester
• CAS NO: 881384-32-3
• Molecular Formula: C₁₇H₁₆F₃N₃O₃S
• Molecular Weight: 399.3874496
• Mol File: 881384-32-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Methyl 2-(4-(2-(trifluoroMethyl)benzoyl)piperazin-1-yl)thiazole-5-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-(4-(2-(trifluoroMethyl)benzoyl)piperazin-1-yl)thiazole-5-carboxylate(881384-32-3)
• EPA Substance Registry System: Methyl 2-(4-(2-(trifluoroMethyl)benzoyl)piperazin-1-yl)thiazole-5-carboxylate(881384-32-3)

Safety Data

• Hazardous Substances Data: 881384-32-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 2-(4-(2-(trifluoromethyl)benzoyl)piperazin-1-yl)thiazole-5-carboxylate is used as a potential pharmaceutical agent for its possible inhibitory or modulatory effects on certain biochemical pathways or receptors. Its unique structure, including a thiazole ring, piperazine moiety, and trifluoromethylbenzoyl group, suggests it may have biological activity that could be harnessed for therapeutic purposes. Further research and testing are required to explore its specific pharmacological properties and potential applications in treating various conditions.

Upstream product

• 312-94-7 2-trifluoromethylbenzoyl chloride 
• 840491-84-1 4-(2-trifluoromethylbenzoyl)piperazine-1-carboxylic acid t-butyl ester 
• 6633-61-0 methyl 2-aminothiazole-5-carboxylate 
• 881384-29-8 N,N-bis(2-chloroethyl)-2-trifluoromethyl-benzamide 
• 179534-78-2 piperazine-1-yl-(2-trifluoromethylphenyl)methanone 
• 54045-74-8 methyl 2-bromo-1,3-thiazole-5-carboxylate 

Downstream Products

• 916888-66-9 MF-152 
• 916888-64-7 2-{4-[2-(trifluoromethyl)benzoyl]piperazin-1-yl}-1,3-thiazole-5-carboxylic acid 

Relevant articles and documents

Heterocyclic Derivatives for the Treatment of Diseases Mediated by Stearoyl-Coa Desaturase Enzymes

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where x, y, G, J, K, L, M, W, V, R2, R3, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

AZACYCLOHEXANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE

Azacyclohexane derivatives of structural formula I are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease, atherosclerosis; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and liver steatosis.